Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | SMO | Q99835 | 5/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8311633 | 0.84 | ATM (0.56) | KMT2ASMN1; SMN2TDP1ALDH1A1KDM4E | |
| SCHEMBL12204047 | 0.82 | ATM (0.54) | KMT2ASMN1; SMN2TDP1ALDH1A1MEN1 | |
| SCHEMBL20353643 | 0.81 | HSD11B1 (0.51) | KMT2ATDP1ALDH1A1KDM4EMEN1 | |
| SCHEMBL18389988 | 0.80 | HRH3 (0.47) | KMT2ATDP1ALDH1A1KDM4EMEN1 | |
| SCHEMBL19012531 | 0.80 | ALDH1A1 (0.42) | KMT2ATDP1ALDH1A1KDM4EMEN1 | |
| SCHEMBL18016684 | 0.80 | CYP1A2 (0.46) | KMT2AHTTSMN1; SMN2TDP1CYP1A2 | |
| SCHEMBL12203746 | 0.79 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1KDM4ELMNAHPGD | |
| SCHEMBL24308611 | 0.79 | L3MBTL1 (0.47) | KMT2ATDP1MEN1HTR1A | |
| Hydrochloric Acid SCHEMBL5489326 | 0.78 | GNAI3 (0.41) | KMT2ATDP1ALDH1A1KDM4EMEN1 | |
| SCHEMBL21733134 | 0.78 | ALDH1A1 (0.37) | KMT2AHTTSMN1; SMN2TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3124482-B1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO LTD (CN) | 2019-09-11 | — | — | EP | disclosed |
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-06-22 | — | — | US | disclosed |
| US-20170096425-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2017-04-06 | — | — | US | disclosed |
| EP-3124482-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-02-01 | — | — | EP | disclosed |
| WO-2017011776-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2017-01-19 | — | — | WO | disclosed |
| EP-1944305-B1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LTD (GB) | 2011-10-19 | — | — | EP | disclosed |
| US-20090312325-A1 | Quinoline Derivatives As Phosphodiesterase Inhibitors | BALDWIN IAN ROBERT | 2009-12-17 | — | — | US | disclosed |
| US-20090312325-A1 | Quinoline Derivatives As Phosphodiesterase Inhibitors | BALDWIN IAN ROBERT | 2009-12-17 | — | — | US | disclosed |
| US-7572915-B2 | 4-[(3-methylphenyl)amino]-6-(methylsulfonyl)-3-quinolinecarboxamide; asthma, COPD, allergic rhinitis, or rheumatoid arthritis in a human | GLAXO GROUP LIMITED (GB) | 2009-08-11 | — | — | US | disclosed |
| US-7572915-B2 | 4-[(3-methylphenyl)amino]-6-(methylsulfonyl)-3-quinolinecarboxamide; asthma, COPD, allergic rhinitis, or rheumatoid arthritis in a human | GLAXO GROUP LIMITED (GB) | 2009-08-11 | — | — | US | disclosed |
| US-7566786-B2 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2009-07-28 | — | — | US | disclosed |
| US-7566786-B2 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2009-07-28 | — | — | US | disclosed |
| EP-1944305-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2008-07-16 | — | — | EP | disclosed |
| EP-1633748-B1 | QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-03-05 | — | — | EP | disclosed |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
| WO-2004103998-A1 | QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096425-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | KMT2A 1448/4885HTT 4246/4885SMN1; SMN2 989/4885 |
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | SMO, GLI1, SHH | KMT2A 325/4885HTT 1275/4885SMN1; SMN2 4029/4885 |
| US-20090312325-A1 | Quinoline Derivatives As Phosphodiesterase Inhibitors | PDE3B, PDE4B, PDE4A | KMT2A 2592/4885HTT 3765/4885SMN1; SMN2 3054/4885 |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | KMT2A 2592/4885HTT 3765/4885SMN1; SMN2 3054/4885 |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | KMT2A 2592/4885HTT 3765/4885SMN1; SMN2 3054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.